Author:
Graff Jordan M.,Sheth Veeral S.,Chang Robert T.,Menezes Alicia R.,Barteselli Giulio,Malhotra Varun K.
Abstract
OBJECTIVES:
To describe conjunctiva and Tenon's capsule handling during the Port Delivery System with ranibizumab (PDS) implant insertion procedure including up-front assessments, planning, and instrumentation, with emphasis placed on the peritomy, scleral dissection, and closure steps.
METHODS:
Surgical pearls based on experience accumulated in the PDS clinical trial program in patients with retinal diseases.
RESULTS:
Preoperative preparation, specific instruments, and meticulous techniques are key to optimizing surgical outcomes. Before surgery, assessment of factors that affect conjunctival integrity and an in-office conjunctiva examination are conducted. Gentle, purposeful conjunctiva and Tenon's capsule handling with nontoothed forceps and suturing with a BV needle are recommended to prevent tissue damage. The peritomy is 6 mm by 6 mm, centered around the planned implant location in the superotemporal quadrant. A complete sub-Tenon's capsule dissection is achieved using a wide, robust lateral and posterior dissection technique to free tissue from the sclera and minimize tension. The globe is stabilized during scleral cutdown by grasping the sclera with fine-toothed forceps away from the incision edge to prevent tissue delamination. When closing the peritomy, both the conjunctiva and Tenon's capsule are completely captured and sutured with scleral anchoring at the apex of the peritomy to help prevent conjunctival retraction and erosion. Mitigation and detection of adverse events is critical to successful surgical outcomes.
CONCLUSIONS:
The PDS implant insertion procedure is straightforward, but it requires planned preoperative preparation, specific instruments, and meticulous techniques. The surgical pearls described here offer insights for optimizing outcomes.
[
Ophthalmic Surg Lasers Imaging Retina
. 2022;53:266–273.]
Reference35 articles.
1. METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
2. Campochiaro P, Singh N, Kardatzke D. Primary analysis results of the phase 3 Archway trial of the Port Delivery System with ranibizumab for patients with neovascular AMD. In: 38th Annual Scientific Meeting of the American Society of Retina Specialists. 2020.
3. SUSVIMOTM (ranibizumab injection) Instructions for use. Genentech, Inc., a member of the Roche Group, South San Francisco, CA. October 2021.
4. Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
5. The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献